UL

Ricerca Biosciences collaborates with Fulcrum Pharma

Friday, March 4, 2011 02:13 PM

Ricerca Biosciences, a preclinical CRO, has partnered with Fulcrum Pharma, an Aptiv Solutions company and a provider of drug development consulting and regulatory services. The collaboration aims to help biopharmaceutical companies move a candidate from development to clinical evaluation more efficiently.

More... »

ITI, Takeda in collaboration

Thursday, March 3, 2011 02:40 PM

Intra-Cellular Therapies has entered into a preclinical discovery deal with Takeda to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors for cognitive impairment associated with schizophrenia and a variety of psychiatric and neurological diseases, according to FierceBiotech.

More... »

Clinipace Worldwide acquires Regulus Pharmaceutical Consulting

Tuesday, March 1, 2011 11:56 AM

Clinipace Worldwide, a global digital CRO based in Morrisville, N.C., has acquired Regulus Pharmaceutical Consulting, a regulatory affairs and quality assurance consultancy based in Boulder, Colo.  

More... »

Report: Drug discovery industry must embrace open source innovation to speed process, boost bottom lines

Monday, January 3, 2011 07:30 AM

To meet the challenges of research and development, the pharmaceutical industry must adopt more open source innovation—a concept that has been used for nearly three decades by the information technology sector—to promote innovation in the drug discovery process and boost bottom lines, according to a new report by Frost & Sullivan.

More... »

Four clinical research firms become one global services organization to target niche areas

Monday, September 20, 2010 07:18 AM

Four small and mid-sized clinical research service companies—Averion International, Trio Clinical Research, Fulcrum Pharma and Clin-Research/ADDPLAN—have merged into one global biopharmaceutical and medical device development services organization that will focus on niche areas, including adaptive trials and new technologies, which can help sponsors make decisions about their drug candidates faster.

More... »

Investors to roll three acquisitions into one adaptive trials CRO

Monday, August 16, 2010 08:45 AM

More proof that the markets are improving: equity investors the Halifax Group and SV Life Sciences have acquired three companies that they will roll up into one, yet-to-be-named, adaptive trials-focused, CRO-like entity.

More... »

Covance Launches Discovery and Translational Services Division

Monday, May 17, 2010 12:59 PM

Covance has reorganized its early-stage drug development work into a new division dedicated to discovery services, antibody products and immunology. The new group, Discovery and Translational Services, integrates the CRO’s Biomarker Center for Excellence, formed in 2009, with its Genomics Laboratory and existing partnerships with Caprion Proteomics and Rules-Based Medicine. 

More... »

SIRO Clinpharm Partners with DreamCIS in South Korea

Thursday, February 11, 2010 12:30 PM

Indian contract research organization (CRO) SIRO Clinpharm is partnering with South Korean CRO DreamCIS to expand SIRO’s services in the Asia-Pacific region.

More... »

ICON Founder to Retire as Board Chairman

Friday, December 18, 2009 07:23 AM

John Climax will retire as board chairman of Dublin-based contract research organization (CRO) ICON, effective December 31. Climax founded the company 19 years ago. He will remain as a board member, while Bruce Given steps into the role of chairman. Given, a healthcare products consultant, has served on ICON’s board for five years. Prior to becoming a consultant, he was president and CEO of Encysive Pharmaceuticals.

More... »

Schulman Associates IRB Expands into Canada

Tuesday, November 3, 2009 08:31 AM

Cincinnati-based Schulman Associates IRB has expanded its institutional review board (IRB) services into Canada. For North American studies, which are conducted in both the U.S. and Canada, Canadian and U.S. board members will review the research together to maintain consistency.

More... »